4
Changes in Ownership
NEKTAR THERAPEUTICS Filed Acc 0001209191-19-057492
Chief R&D Officer sold 3,960 shares at $17.97 ($71,161)
From the SEC's structured data for this filing
Trades in this filing
Zalevsky Jonathan · Chief R&D Officer
Table I: Non-derivative
1 line| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2019-11-18 | Sale : show line 1 in the form | −3,960 | $17.97 | $71,161 | 291,697 | D |
| Open-market sales · 3,960 sh · avg $17.97 · $71,161 | ||||||
Loading xslF345X03/doc4.xml…